Cancer Antigen 19-9 Enzyme Conjugate Reagent
- UID
- MFG/IVD/2021/000078_f284bfc8a2cbf4ac8bcc7cd64caccbf7_ee1c3539c37bfcd23b22f9f75a27d2cf
- Device class
- Class C
- Brand name
- AFP+CEA+PSA
- License holder
- Tosoh India Pvt. Ltd.
- Approving authority
- Central Drug Standards Control Organization, West Zone
- Product information
- For in-vitro diagnostic use only for quantitative determination of CA-19.9 in Human Serum by a Microplate Enzyme Immunoassay (AFP+CEA+PSA)
Cancer Antigen 19-9 Enzyme Conjugate Reagent is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID MFG/IVD/2021/000078_f284bfc8a2cbf4ac8bcc7cd64caccbf7_ee1c3539c37bfcd23b22f9f75a27d2cf. This device is marketed under the brand name AFP+CEA+PSA. The license holder is Tosoh India Pvt. Ltd., and it is classified as Device Class Class C. The approving authority is Central Drug Standards Control Organization, West Zone.
This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.